Applications of LncRNA for diagnosing patients with breast cancer chemotherapy-related myocardial injury

A technology for myocardial injury and breast cancer, which is applied in the field of biomedicine to achieve the effect of reducing the possibility of myocardial injury, high sensitivity and specificity

Active Publication Date: 2020-05-08
青岛山大齐鲁医院(山东大学齐鲁医院(青岛))
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the research of lncRNA in human diseases is still in its infancy, and the mechanism of lncRNA in breast cancer chemotherapy-related myocardial injury still needs to be further studied and revealed

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Applications of LncRNA for diagnosing patients with breast cancer chemotherapy-related myocardial injury
  • Applications of LncRNA for diagnosing patients with breast cancer chemotherapy-related myocardial injury
  • Applications of LncRNA for diagnosing patients with breast cancer chemotherapy-related myocardial injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Example 1 Screening for differential expression of long non-coding RNAs in breast cancer chemotherapy-related myocardial injury

[0025] 1. Research object

[0026] The blood of 5 breast cancer patients with myocardial injury after chemotherapy was selected (group B), and the blood of corresponding breast cancer patients before chemotherapy (group A) (patients without myocardial injury before chemotherapy) were selected. At the same time, 5 cases of breast cancer after chemotherapy were selected. The blood of patients without myocardial injury (group D) and the blood of corresponding breast cancer patients before chemotherapy (group C) were reviewed and approved by the hospital ethics committee, and all patients signed a written informed notice before enrollment.

[0027] 2. RNA extraction

[0028] (1) After clinical serum samples are collected, put them in a centrifuge, centrifuge at 12000r / min for 10min, repeat twice, and store the obtained serum samples in a -80°C r...

Embodiment 2

[0045] Example 2 Real-time quantitative PCR to verify the expression difference of LINC01471 gene

[0046] 1. Sample selection

[0047] The blood of 20 breast cancer patients with myocardial injury after chemotherapy (group B) and the blood of corresponding breast cancer patients before chemotherapy (group A) (group A) (patients without myocardial injury before chemotherapy) were selected. This study was reviewed by the hospital ethics committee All patients signed a written informed notice before enrollment.

[0048] 2. Fluorescent quantitative PCR detection

[0049] (1) The extraction steps of serum RNA are the same as in Example 1

[0050] (2) Reverse transcription reaction

[0051] Genomic DNA removal

[0052] Reagent

[0053] Reagent Usage amount 5×gDNA Eraser Buffer 2.0 μl gDNA Eraser 1μl Total RNA 1μg RNase Free dH2O up to 10 μl

[0054] Reaction conditions

[0055] 2 minutes at 42°C, 4°C.

[0056] reverse transcriptio...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a long non-coding RNA gene marker for diagnosing breast cancer chemotherapy-related myocardial injury. The long non-coding RNA is LINC01471. Through the discovery of the screening of a chip technology, compared with breast cancer patients before chemotherapy, the expression of the LINC01471 can be significantly enhanced in the blood of the patients with myocardial injury after the chemotherapy, and results can be further verified in fluorescence quantitation PCR. The beneficial effects are as follows: a molecular marker for diagnosing the breast cancer chemotherapy-related myocardial injury is provided; and whether the breast cancer patients have myocardial injury can be judged at the early stage of the chemotherapy by detecting the molecular marker, so that corresponding treatment measures can be taken as early as possible, and the possibility of the myocardial injury occurring in the breast cancer patients during treatment can be decreased. Compared with biochemical markers, the provided lncRNA marker has the characteristics of being high in sensitivity and strong in specificity.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to the application of an LncRNA in the diagnosis of patients with myocardial injury associated with breast cancer chemotherapy. Background technique [0002] Breast cancer is a common malignant tumor in women. The incidence rate of breast cancer in developed countries such as Europe and the United States and in big cities such as Shanghai in China has become the first among female malignant tumors. At present, comprehensive treatment methods for breast cancer mainly include surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy, among which chemotherapy plays an important role. Although, with the continuous improvement of the treatment level of breast cancer, the patient's survival period is continuously prolonged, but after chemotherapy treatment, the patient's complications are also continuously increasing, and myocardial injury caused by chemothe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6883C12N15/113
CPCC12Q1/6883C12Q2600/158C12Q2600/178
Inventor 王兆平王颖翠
Owner 青岛山大齐鲁医院(山东大学齐鲁医院(青岛))
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap